LZ901 Herpes Zoster Vaccine
Clinical caseInfectious diseases2 min
A 62-year-old adult asks about vaccination to reduce the risk of herpes zoster. You review evidence from a multicentre, randomised, double-blind, placebo-controlled phase 3 trial of LZ901 in adults 40 years of age or older.